A retrospective research of adjuvant albumin-bound paclitaxel plus S-1 after D2 gastrectomy versus oxaliplatin plus S-1 in gastric most cancers


  • Sung, H. et al. International most cancers statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 international locations. CA Most cancers J. Clin. 71, 209–249 (2021).

    Article 
    PubMed 

    Google Scholar
     

  • Xia, C. et al. Most cancers statistics in China and United States, 2022: profiles, traits, and determinants. Chin. Med. J. (Engl) 135, 584–590 (2022).

    Article 
    PubMed 

    Google Scholar
     

  • D’Angelica, M. et al. Patterns of preliminary recurrence in utterly resected gastric adenocarcinoma. Ann. Surg. 240, 808–816 (2004).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Sakuramoto, S. et al. Adjuvant chemotherapy for gastric most cancers with S-1, an oral fluoropyrimidine. N. Engl. J. Med. 357, 1810–1820 (2007).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Bang, Y. J. et al. Adjuvant capecitabine and oxaliplatin for gastric most cancers after D2 gastrectomy (CLASSIC): a part 3 open-label, randomised managed trial. Lancet 379, 315–321 (2012).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Kakeji, Y. et al. Three-year outcomes of a randomized part III trial evaluating adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric most cancers: JACCRO GC-07. Gastric Most cancers 25, 188–196 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Zhang, X. et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in sufferers with domestically superior gastric or gastro-oesophageal junction adenocarcinoma present process D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, part 3 randomised managed trial. Lancet Oncol 22, 1081–1092 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Xu, J. et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction most cancers: The ORIENT-16 randomized medical trial. JAMA 330, 2064–2074 (2023).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Liu, T. et al. First-line nivolumab plus chemotherapy vs. chemotherapy in sufferers with superior gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese language subgroup evaluation. Int. J. Most cancers 152, 749–760 (2023).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for superior gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, part 3 trial. Lancet 398, 27–40 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Shitara, Okay. et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in domestically superior gastric or gastro-oesophageal most cancers (KEYNOTE-585): an interim evaluation of the multicentre, double-blind, randomised part 3 research. Lancet Oncol. 25, 212 (2023).

    Article 
    PubMed 

    Google Scholar
     

  • Terashima, M., Kang, Y.Okay., Kim, Y.-W., Boku, N., Chung, H.-C.-C., Chen, J.-S., Ji, J., Yeh, T.-S., Chen, L.-T., Ryu, M.-H., Kim, J.-G., Omori, T., Rha, S.-Y., Kim, T.-Y., Ryu, Okay.-W., Sakuramoto, S., Nishida, Y., Fukushima, N., Yamada, T. Sasako, M. ATTRACTION-5: A part 3 research of nivolumab plus chemotherapy as postoperative adjuvant remedy for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) most cancers. In: 2023 ASCO Annual Assembly I: gastrointestinal most cancers—gastroesophageal, pancreatic, and hepatobiliary, (abstr 4000), (2023)

  • Guven, D. C. et al. The affiliation between albumin ranges and survival in sufferers handled with immune checkpoint inhibitors: A scientific assessment and meta-analysis. Entrance. Mol. Biosci. 9, 1039121 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Dall’Olio, F. G. et al. Immortal time bias within the affiliation between toxicity and response for immune checkpoint inhibitors: A meta-analysis. Immunotherapy 13, 257–270 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Rizzo, A. et al. Hypertransaminasemia in most cancers sufferers receiving immunotherapy and immune-based mixtures: The MOUSEION-05 research. Most cancers Immunol. Immunother. 72, 1381–1394 (2023).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Al-Batran, S. E. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for domestically superior, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, part 2/3 trial. Lancet 393, 1948–1957 (2019).

    Article 
    PubMed 

    Google Scholar
     

  • Al-Batran, S. E. et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in sufferers with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): Outcomes from the part 2 a part of a multicentre, open-label, randomised part 2/3 trial. Lancet Oncol. 17, 1697–1708 (2016).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Kang, Y. Okay. et al. PRODIGY: A part III research of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgical procedure and adjuvant S-1 versus surgical procedure and adjuvant S-1 for resectable superior gastric most cancers. J. Clin. Oncol. 39, 2903–2913 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Giampieri, R. et al. Influence of signet-ring cell histology within the administration of sufferers with non-metastatic gastric most cancers: Outcomes from a retrospective multicenter evaluation evaluating FLOT perioperative chemotherapy vs. surgical procedure adopted by adjuvant chemotherapy. Cancers (Basel) 15, 3342 (2023).

    Article 
    PubMed 

    Google Scholar
     

  • Tsuburaya, A. et al. Sequential paclitaxel adopted by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric most cancers (SAMIT): A part 3 factorial randomised managed trial. Lancet Oncol. 15, 886–893 (2014).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Su, L. et al. POF (paclitaxel/oxaliplatin/5-fluorouracil/leucovorin) vs. SOX/CAPOX/FOLFOX as a postoperative adjuvant chemotherapy for curatively resected stage III gastric most cancers: Examine protocol for a randomized managed trial, FNF-014 trial. Entrance Med. (Lausanne) 9, 861777 (2022).

    Article 
    PubMed 

    Google Scholar
     

  • Shitara, Okay. et al. Nab-paclitaxel versus solvent-based paclitaxel in sufferers with beforehand handled superior gastric most cancers (ABSOLUTE): An open-label, randomised, non-inferiority, part 3 trial. Lancet Gastroenterol. Hepatol. 2, 277–287 (2017).

    Article 
    PubMed 

    Google Scholar
     

  • He, M. M. et al. Section II medical trial of S-1 plus nanoparticle albumin-bound paclitaxel in untreated sufferers with metastatic gastric most cancers. Most cancers Sci. 109, 3575–3582 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Cui, Y. et al. Section I research of adjuvant chemotherapy with nab-paclitaxel and S-1 for stage III Lauren’s diffuse-type gastric most cancers after D2 resection (NORDICA research). Most cancers Med. 12, 1114–1121 (2023).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Cheng, X. et al. Adjuvant albumin-bound paclitaxel mixed with S-1 vs. oxaliplatin mixed with capecitabine after D2 gastrectomy in sufferers with stage III gastric adenocarcinoma: A part III multicenter, open-label, randomized managed medical trial protocol. BMC Most cancers 21, 56 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Cheng, X. et al. The function of oxaliplatin within the adjuvant setting of various Lauren’s kind of gastric adenocarcinoma after D2 gastrectomy: An actual-world research. Gastric Most cancers 22, 587–597 (2019).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Sasaki, Y. et al. Section II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric most cancers. Most cancers Sci. 105, 812–817 (2014).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ma, J. et al. Evaluation of the efficacy and security of paclitaxel (albumin-bound) mixed with S-1 and oxaliplatin mixed with S-1 within the first-line remedy of superior gastric most cancers: A cohort research. J. Gastrointest. Oncol. 13, 630–636 (2022).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Hot Topics

    Related Articles